Mylan Laboratories (MYL) Levothyroxine Sodium Tablets USP Approved as Generic Equivalent to Levothroid

January 3, 2007 9:27 AM EST

Mylan Laboratories Inc. (NYSE: MYL) announced that the U.S. Food and Drug Administration (FDA) has granted the company approval to market its currently approved Levothyroxine Sodium Tablets, USP as a bioequivalent and, therefore, therapeutically equivalent product to Levothroid Tablets (manufactured by Lloyd Pharmaceuticals for Forest Laboratories Inc. (NYSE: FRX)).

Total U.S. sales for all Levothyroxine brands and generic equivalents were approximately $1 billion for the 12-month period ended Sept. 30, 2006, according to data from IMS Health.


Related Categories

FDA

Stocks Mentioned

FRX 28.67

+0.28 +0.99%
Volume: 2,233,754
Track FRX

MYL 17.47

+0.05 +0.29%
Volume: 4,514,423
Track MYL


Add Your Comment